CN114585416B - 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体 - Google Patents

用于调节免疫应答和治疗疾病的btla结合（cd272）抗体 Download PDF

Info

Publication number
CN114585416B
CN114585416B CN202080040939.4A CN202080040939A CN114585416B CN 114585416 B CN114585416 B CN 114585416B CN 202080040939 A CN202080040939 A CN 202080040939A CN 114585416 B CN114585416 B CN 114585416B
Authority
CN
China
Prior art keywords
seq
antibody
btla
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080040939.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN114585416A (zh
Inventor
B·A·扎贝尔
J·A·利平科特
Y·郑
M·V·饶
M·谭
D·P·迈宁格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuria Biotechnology Co ltd
Kuria Intellectual Property Holdings LLC
Trianni Inc
Original Assignee
Lake Pharmaceutical Co ltd
Trianni Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lake Pharmaceutical Co ltd, Trianni Inc filed Critical Lake Pharmaceutical Co ltd
Priority to CN202411950244.6A priority Critical patent/CN119735682A/zh
Publication of CN114585416A publication Critical patent/CN114585416A/zh
Application granted granted Critical
Publication of CN114585416B publication Critical patent/CN114585416B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080040939.4A 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体 Active CN114585416B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411950244.6A CN119735682A (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962827744P 2019-04-01 2019-04-01
US62/827,744 2019-04-01
PCT/US2020/025936 WO2020205849A1 (en) 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411950244.6A Division CN119735682A (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体

Publications (2)

Publication Number Publication Date
CN114585416A CN114585416A (zh) 2022-06-03
CN114585416B true CN114585416B (zh) 2025-01-17

Family

ID=70296156

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080040939.4A Active CN114585416B (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体
CN202411950244.6A Pending CN119735682A (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411950244.6A Pending CN119735682A (zh) 2019-04-01 2020-03-31 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体

Country Status (8)

Country Link
US (2) US11384146B2 (https=)
EP (1) EP3946622A1 (https=)
JP (2) JP7596298B2 (https=)
KR (1) KR20220047536A (https=)
CN (2) CN114585416B (https=)
CA (1) CA3135836A1 (https=)
IL (1) IL286838A (https=)
WO (1) WO2020205849A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546713A (ja) * 2020-10-23 2023-11-07 アナプティスバイオ インコーポレイティッド Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法
MX2024007054A (es) * 2021-12-10 2024-09-04 Merck Sharp & Dohme Llc Aglutinantes de mesotelina humana.
US20250304693A1 (en) * 2022-01-29 2025-10-02 Hifibio, Inc. Anti-btla antibodies and uses thereof in treating cancer
US20230322929A1 (en) * 2022-04-12 2023-10-12 Shanghai Junshi Biosciences Co., Ltd. Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy
CN120322455A (zh) * 2022-07-19 2025-07-15 舒泰神(加州)生物科技有限公司 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025250861A1 (en) * 2024-05-31 2025-12-04 Icahn School Of Medicine At Mount Sinai Broadly neutralizing anti-hcmv antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101888878A (zh) * 2007-09-26 2010-11-17 健泰科生物技术公司 新型抗体
CN108925136A (zh) * 2015-12-02 2018-11-30 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP1560593B1 (en) 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
BR112012007875A2 (pt) * 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
MX2018010295A (es) * 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
KR20230119259A (ko) * 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101888878A (zh) * 2007-09-26 2010-11-17 健泰科生物技术公司 新型抗体
CN108925136A (zh) * 2015-12-02 2018-11-30 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体

Also Published As

Publication number Publication date
CN114585416A (zh) 2022-06-03
JP2025041629A (ja) 2025-03-26
JP2022528005A (ja) 2022-06-07
JP7596298B2 (ja) 2024-12-09
IL286838A (en) 2021-10-31
US20230340123A1 (en) 2023-10-26
WO2020205849A1 (en) 2020-10-08
KR20220047536A (ko) 2022-04-18
US20200325230A1 (en) 2020-10-15
CN119735682A (zh) 2025-04-01
US11384146B2 (en) 2022-07-12
CA3135836A1 (en) 2020-10-08
EP3946622A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
CN114585416B (zh) 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体
US12404327B2 (en) LILRB3-binding molecules and uses therefor
US20240150462A1 (en) Lilrb1 and lilrb2-binding molecules and uses therefor
KR20210138674A (ko) Tsg-6 항체 및 그 용도
TWI857009B (zh) Ｆｃｍｒ結合分子及其用途
EA046937B1 (ru) Lilrb3-связывающие молекулы и варианты их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: California, USA

Patentee after: Kuria Biotechnology Co.,Ltd.

Country or region after: U.S.A.

Patentee after: Trianni S.A.

Address before: California, USA

Patentee before: Lake Pharmaceutical Co.,Ltd.

Country or region before: U.S.A.

Patentee before: Trianni S.A.

CP03 Change of name, title or address
TR01 Transfer of patent right

Effective date of registration: 20250123

Address after: New York, United States

Patentee after: Kuria Intellectual Property Holdings LLC

Country or region after: U.S.A.

Patentee after: Trianni S.A.

Address before: California, USA

Patentee before: Kuria Biotechnology Co.,Ltd.

Country or region before: U.S.A.

Patentee before: Trianni S.A.

TR01 Transfer of patent right